CIK 0001393434
- Large accelerated filer
OCULAR THERAPEUTIX, INC
Sign in to watch- Ticker
- OCUL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 781-357-4000
- Business address
- 14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA, 01730
- Former names
- I-THERAPEUTIX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $799,174
- in 9 filings, $788K under 10b5-1 plans
Net −$799,174. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dugel Pravin −$233K Reporting owner sold <1% of stake
- Saroj Namrata −$232K Chief Business Officer sold 14% of stake
- Heier Jeffrey S. −$112K Chief Scientific Officer sold 4% of stake
- Kaiser Peter −$103K Chief Development Officer sold 5% of stake
- Anderman Todd −$87K Chief Legal Officer sold 8% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-22 | Dugel Pravin Executive Chairman | Grant or award · Stock Option (Right to Buy) | +1,282,469 | 1,282,469 | ||
| 2024-02-22 | Nayak Sanjay Chief Strategy Officer | Grant or award | +80,300 | 180,300 | ||
| 2024-02-22 | Nayak Sanjay Chief Strategy Officer | Grant or award · Stock Option (Right to Buy) | +244,550 | 244,550 | ||
| 2024-02-05 | White Christopher G Chief Business Officer | Sale | +5,910 | $4.86 | $29K | 123,689 |
| 2024-02-05 | Strassburger Philip C. General Counsel | Sale | +6,029 | $4.86 | $29K | 161,493 |
| 2024-02-05 | Ozden Rabia Gurses Chief Medical Officer | Sale | +6,346 | $4.86 | $31K | 153,054 |
| 2024-02-05 | Notman Donald Chief Financial Officer | Sale | +6,212 | $4.86 | $30K | 195,356 |
| 2024-02-05 | Mattessich Antony C. President and CEO | Sale | +19,642 | $4.86 | $95K | 588,701 |
| 2024-02-03 | White Christopher G Chief Business Officer | Grant or award | +39,980 | 129,599 | ||
| 2024-02-03 | White Christopher G Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2024-02-03 | Strassburger Philip C. General Counsel | Grant or award | +58,304 | 167,522 | ||
| 2024-02-03 | Strassburger Philip C. General Counsel | Grant or award · Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2024-02-03 | Ozden Rabia Gurses Chief Medical Officer | Grant or award | +66,633 | 159,400 | ||
| 2024-02-03 | Ozden Rabia Gurses Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2024-02-03 | Notman Donald Chief Financial Officer | Grant or award | +61,636 | 201,568 | ||
| 2024-02-03 | Notman Donald Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +185,000 | 185,000 | ||
| 2024-02-03 | Mattessich Antony C. President and CEO | Grant or award | +180,400 | 608,343 | ||
| 2024-02-03 | Mattessich Antony C. President and CEO | Grant or award · Stock Option (Right to Buy) | +549,400 | 549,400 | ||
| 2024-01-31 | Notman Donald Chief Financial Officer | Sale | −6,433 | $4.95 | $32K | 139,932 |
| 2024-01-31 | Ozden Rabia Gurses Chief Medical Officer | Sale | −7,764 | $4.95 | $38K | 92,767 |
Page 9 of 17 · 327 trades